- CA$120.45m
- CA$105.54m
- CA$35.03m
- 89
- 50
- 76
- 84
Annual income statement for Biosyent, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 22.3 | 28.6 | 27.9 | 31.6 | 35 |
| Cost of Revenue | |||||
| Gross Profit | 17.4 | 22.6 | 22.9 | 25.6 | 27.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.3 | 20.4 | 20.9 | 24.1 | 26.3 |
| Operating Profit | 5.03 | 8.18 | 6.98 | 7.47 | 8.75 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 5.24 | 8.38 | 7.43 | 8.53 | 9.78 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3.8 | 6.28 | 5.46 | 6.46 | 7.27 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 3.8 | 6.28 | 5.46 | 6.46 | 7.27 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3.8 | 6.28 | 5.46 | 6.46 | 7.27 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.29 | 0.488 | 0.441 | 0.531 | 0.643 |
| Dividends per Share |